Beutel, Goodman & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $670K | Buy |
17,450
+4,670
| +37% | +$179K | ﹤0.01% | 106 |
|
|
2025
Q1 | $495K | Buy |
12,780
+80
| +0.6% | +$3.1K | ﹤0.01% | 115 |
|
|
2024
Q4 | $429K | Sell |
12,700
-590
| -4% | -$19.9K | ﹤0.01% | 68 |
|
|
2024
Q3 | $543K | Buy |
13,290
+130
| +1% | +$5.31K | ﹤0.01% | 67 |
|
|
2024
Q2 | $506K | Hold |
13,160
| – | – | ﹤0.01% | 68 |
|
|
2024
Q1 | $564K | Buy |
13,160
+110
| +0.8% | +$4.71K | ﹤0.01% | 66 |
|
|
2023
Q4 | $483K | Buy |
13,050
+4,620
| +55% | +$171K | ﹤0.01% | 67 |
|
|
2023
Q3 | $305K | Buy |
8,430
+20
| +0.2% | +$724 | ﹤0.01% | 66 |
|
|
2023
Q2 | $299K | Buy |
8,410
+1,260
| +18% | +$44.8K | ﹤0.01% | 65 |
|
|
2023
Q1 | $254K | Buy |
7,150
+920
| +15% | +$32.7K | ﹤0.01% | 65 |
|
|
2022
Q4 | $218K | Sell |
6,230
-3,100
| -33% | -$108K | ﹤0.01% | 67 |
|
|
2022
Q3 | $274K | Sell |
9,330
-890
| -9% | -$26.1K | ﹤0.01% | 64 |
|
|
2022
Q2 | $556K | Sell |
10,220
-344
| -3% | -$18.7K | ﹤0.01% | 62 |
|
|
2022
Q1 | $575K | Buy |
10,564
+776
| +8% | +$42.2K | ﹤0.01% | 60 |
|
|
2021
Q4 | $539K | Buy |
9,788
+804
| +9% | +$44.3K | ﹤0.01% | 57 |
|
|
2021
Q3 | $429K | Hold |
8,984
| – | – | ﹤0.01% | 58 |
|
|
2021
Q2 | $447K | Buy |
8,984
+880
| +11% | +$43.8K | ﹤0.01% | 59 |
|
|
2021
Q1 | $361K | Buy |
8,104
+7,136
| +737% | +$318K | ﹤0.01% | 60 |
|
|
2020
Q4 | $44K | Buy |
968
+304
| +46% | +$13.8K | ﹤0.01% | 65 |
|
|
2020
Q3 | $31K | Buy |
+664
| New | +$31K | ﹤0.01% | 65 |
|
|
2020
Q1 | – | Sell |
-284,326
| Closed | -$16.7M | – | 67 |
|
|
2019
Q4 | $16.7M | Sell |
284,326
-60,261
| -17% | -$3.54M | 0.1% | 53 |
|
|
2019
Q3 | $14M | Buy |
+344,587
| New | +$14M | 0.1% | 52 |
|